China National Medicines Corporation Ltd.’s Net Profit Rose 8.7% in First Three Quarters of 2022

China National Medicines Corporation Ltd. (国药集团药业股份有限公司) (600511.SH) reported a net profit of 1.5 billion yuan in the first three quarters of 2022, up 8.7% year-on-year.

Meanwhile, the company posted 34.5 billion yuan in revenue, up 0.7% year-on-year.

At the end of the reporting period, it had 29.3 billion yuan in total assets and 14 billion yuan in total liabilities, with a liability-to-asset ratio of 47.8%.